These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 29361245)

  • 21. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.
    Li X; Zhu Y; Kang H; Zhang Y; Liang H; Wang S; Zhang W
    Cancer Imaging; 2015 Mar; 15(1):4. PubMed ID: 25889239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The value of DCE-MRI in predicting IDH gene mutation of high-grade gliomas].
    Lu HT; Xing W; Zhang YW; Qin HP; Wu RH; Ding JL
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(39):3105-3109. PubMed ID: 31648456
    [No Abstract]   [Full Text] [Related]  

  • 23. Histogram analysis of T2*-based pharmacokinetic imaging in cerebral glioma grading.
    Liu HS; Chiang SW; Chung HW; Tsai PH; Hsu FT; Cho NY; Wang CY; Chou MC; Chen CY
    Comput Methods Programs Biomed; 2018 Mar; 155():19-27. PubMed ID: 29512499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging.
    Jia ZZ; Gu HM; Zhou XJ; Shi JL; Li MD; Zhou GF; Wu XH
    Eur J Radiol; 2015 Sep; 84(9):1805-9. PubMed ID: 26066470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas.
    Conte GM; Altabella L; Castellano A; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Caulo M; Falini A; Anzalone N
    Eur Radiol; 2019 Jul; 29(7):3467-3479. PubMed ID: 30972545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
    Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
    Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
    AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
    Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
    Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intergrating conventional MRI, texture analysis of dynamic contrast-enhanced MRI, and susceptibility weighted imaging for glioma grading.
    Su CQ; Lu SS; Han QY; Zhou MD; Hong XN
    Acta Radiol; 2019 Jun; 60(6):777-787. PubMed ID: 30244590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study.
    Di N; Cheng W; Jiang X; Liu X; Zhou J; Xie Q; Chu Z; Chen H; Wang B
    J Neuroradiol; 2019 May; 46(3):186-192. PubMed ID: 29752976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.
    Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK
    Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic Value of Combining Permeability with T1 Perfusion Parameters in Quantitative Dynamic Contrast-enhanced Magnetic Resonance Imaging for Glioma Grading].
    Sun SJ; Qian HF; Li FQ; Li ZY; Wu X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Dec; 37(6):674-80. PubMed ID: 26725390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
    Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
    J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Utility of Integration of Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast MR Perfusion Employing Split Bolus Technique in Differentiating High-Grade Glioma.
    Malik V; Kesavadas C; Thomas B; N DA; K KK
    Indian J Radiol Imaging; 2024 Jul; 34(3):382-389. PubMed ID: 38912247
    [No Abstract]   [Full Text] [Related]  

  • 37. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach.
    Falk A; Fahlström M; Rostrup E; Berntsson S; Zetterling M; Morell A; Larsson HB; Smits A; Larsson EM
    Neuroradiology; 2014 Dec; 56(12):1031-8. PubMed ID: 25204450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.
    Saini J; Gupta PK; Sahoo P; Singh A; Patir R; Ahlawat S; Beniwal M; Thennarasu K; Santosh V; Gupta RK
    Neuroradiology; 2018 Jan; 60(1):43-50. PubMed ID: 29090331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.